Favipiravir Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 200 mg, 400 mg, 600 mg
Reference Brands: Fabiflu, Favicovid, Covihalt, Avifavir, Avigan, Favira , Favilow(Globally, Not approved in USA & EU)
Category:
Anti Covid Medicines
Favipiravir, an antiviral used for mild to moderate COVID-19, is approved in countries like India, Japan, and Russia, under brands such as Fabiflu, Avigan, and Avifavir. Though not approved in the US or EU, it's widely sourced across Asia, LATAM, and MENA. PharmaB2B platforms connect buyers with trusted Favipiravir exporters and manufacturers, offering bulk supply, global reach, and regulatory-compliant sourcing.
Favipiravir tablet is available in Tablet
and strengths such as 200 mg, 400 mg, 600 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Favipiravir tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Favipiravir tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Favipiravir is a broad-spectrum antiviral used in the treatment of mild to moderate COVID-19 in countries like India, Japan, Russia, and Bangladesh. Commonly available in 200 mg and 400 mg tablets, it is marketed under leading brands such as Fabiflu, Avigan, and Avifavir. While not approved in the US or EU, Favipiravir remains in demand across Asia, the Middle East, and Latin America. Global PharmaB2B platforms connect verified Favipiravir suppliers, manufacturers, and exporters, ensuring regulatory-compliant sourcing, competitive pricing, and bulk availability. Partner with trusted B2B pharmaceutical networks for efficient distribution and international trade.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing